ANI Pharmaceuticals, Inc.ANIPNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +44.75% | +43.43% | +53.12% | +53.58% | +29.64% |
| Gross Profit Growth | +40.98% | +40.57% | +70.22% | +31.12% | +115.39% |
| EBITDA Growth | -32.14% | +8.38% | +129.95% | +0.00% | +417.96% |
| Operating Income Growth | -165.09% | +28.96% | +168.76% | +0.00% | +0.00% |
| Net Income Growth | -989.70% | -13.87% | +0.00% | +0.00% | +0.00% |
| EPS Growth | -1495.94% | -16.67% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | -1510.26% | -16.87% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +2.33% | +2.66% | +2.66% | +3.45% | +3.13% |
| Weighted Average Shares Diluted Growth | +1.18% | +3.21% | +5.11% | +8.70% | +9.17% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -64.55% | +91.53% | +335.35% | +253.17% | +91.47% |
| Free Cash Flow Growth | -66.52% | +10.64% | +431.45% | +394.54% | -51.37% |
| Receivables Growth | +36.80% | +27.79% | +35.86% | +28.65% | +26.77% |
| Inventory Growth | +23.01% | +20.71% | +10.26% | -1.06% | +4.59% |
| Asset Growth | +41.94% | +41.32% | +45.86% | +9.38% | +12.21% |
| Book Value per Share Growth | -8.48% | -9.40% | -6.44% | +13.50% | +22.36% |
| Debt Growth | +118.47% | +118.18% | +117.91% | -48.41% | -47.89% |
| R&D Expense Growth | +68.70% | +0.50% | +126.63% | +21.48% | -26.34% |
| SG&A Expenses Growth | +56.81% | +59.36% | +54.81% | -3.06% | +18.75% |